PMC:7696151 / 89317-89607 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"2653","span":{"begin":194,"end":197},"obj":"Gene"},{"id":"2661","span":{"begin":16,"end":24},"obj":"Species"},{"id":"2679","span":{"begin":203,"end":206},"obj":"Chemical"},{"id":"2706","span":{"begin":30,"end":42},"obj":"Disease"},{"id":"2707","span":{"begin":70,"end":75},"obj":"Disease"},{"id":"2708","span":{"begin":271,"end":289},"obj":"Disease"}],"attributes":[{"id":"A2653","pred":"tao:has_database_id","subj":"2653","obj":"Gene:1641"},{"id":"A2661","pred":"tao:has_database_id","subj":"2661","obj":"Tax:9606"},{"id":"A2679","pred":"tao:has_database_id","subj":"2679","obj":"MESH:D006886"},{"id":"A2706","pred":"tao:has_database_id","subj":"2706","obj":"MESH:D006349"},{"id":"A2707","pred":"tao:has_database_id","subj":"2707","obj":"MESH:D005334"},{"id":"A2708","pred":"tao:has_database_id","subj":"2708","obj":"MESH:D005334"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Furthermore, in patients with valvulopathy and diagnosticated acute Q fever (serologic criteria of a phase II IgG titer ≥ 200 and a phase II IgM titer ≥ 50) the administration as prophylaxis of DCX plus HCQ for at least 12 months resulted to be efficient in preventing Q fever endocarditis."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T229","span":{"begin":70,"end":75},"obj":"Phenotype"},{"id":"T230","span":{"begin":271,"end":276},"obj":"Phenotype"},{"id":"T231","span":{"begin":277,"end":289},"obj":"Phenotype"}],"attributes":[{"id":"A229","pred":"hp_id","subj":"T229","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A230","pred":"hp_id","subj":"T230","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A231","pred":"hp_id","subj":"T231","obj":"http://purl.obolibrary.org/obo/HP_0100584"}],"text":"Furthermore, in patients with valvulopathy and diagnosticated acute Q fever (serologic criteria of a phase II IgG titer ≥ 200 and a phase II IgM titer ≥ 50) the administration as prophylaxis of DCX plus HCQ for at least 12 months resulted to be efficient in preventing Q fever endocarditis."}

{"project":"LitCovid-sentences","denotations":[{"id":"T569","span":{"begin":0,"end":290},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Furthermore, in patients with valvulopathy and diagnosticated acute Q fever (serologic criteria of a phase II IgG titer ≥ 200 and a phase II IgM titer ≥ 50) the administration as prophylaxis of DCX plus HCQ for at least 12 months resulted to be efficient in preventing Q fever endocarditis."}